Skip to main content
26, May 2021
T-cell and antibody immunity after COVID-19 vaccination in healthy and immunocompromised

An exploratory study reported on May 23, 2021, in MedRxiv described changes in T-cell and antibody immunity after mRN

Read more
6, May 2021
Impaired T-cell and antibody responses after COVID-19 infection in transplant recipients

In transplant recipients on chronic immunosuppression, COVID-19 infection is associated with impaired T-cell and anti

Read more
19, Mar 2021
Transplant recipients show impaired antibody responses to the first mRNA vaccine dose.

On March 15, 2021, Boyarski et al.

Read more
5, Jan 2021
COVID-19 Vaccines: Authorized for Emergency Use

Latest Updates: (01/18/2021)

Read more
31, Dec 2020
Recurrent Illness and the Burden of COVID-19

Recurring symptoms lasting several months may require ongoing treatment in some patients who have experienced COVID-1

Read more
29, Dec 2020
COVID-19 variant: Early data

A new variant of the coronavirus that causes COVID-19 has been reported in the UK.

Read more
4, Dec 2020
Increasing COVID-19 Infections in Children

Increasing COVID-19 infections in children

Read more
24, Nov 2020
Morbidity of COVID-19 in Kidney Transplant Patients

Kidney transplant patients are vulnerable to severe COVID-19 infection due to chronic immunosuppression and underlyin

Read more
18, Nov 2020
Healthcare Workers at Significant COVID-19 Risk

Healthcare Workers at Significant COVID-19 Risk

 

Read more
19, Oct 2020
Plexision Awarded Competitive Grant from the National Science Foundation for COVID-19 Immunity Test Development

Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant.

Read more
Subscribe to Media

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact